ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1767

Circulating Plasmablasts As a Source of Anti-Citrullinated Protein Antibodies in Patients with Rheumatoid Arthritis

Priscilla Kerkman, Ellen I.H. van der Voort, Leendert A. Trouw, Tom W.J. Huizinga, René E.M. Toes and Hans Ulrich Scherer, Rheumatology, Leiden University Medical Center, Leiden, Netherlands

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: anti-citrullinated protein/peptide antibodies (ACPA), B cells, pathogenesis, plasma cells and rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: B-cell Biology and Targets in Autoimmune Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Anti citrullinated protein antibodies (ACPA) are highly specific for rheumatoid arthritis (RA) and predict disease onset and severity. Accumulating evidence indicates that ACPA could play an important role in RA pathogenesis by contributing to inflammation and joint destruction. So far, however, little is known on the characteristics of ACPA producing B cells. In this study, we set out to define ACPA producing B cells in more detail in order to allow for specific targeting of these cells.

Methods:

Peripheral blood CD19 positive B cells from patients with ACPA positive RA (n=30) were isolated using magnetic beads. In addition, B cell subsets were purified by FACS-sorting based on the expression of surface markers CD19, CD20 and CD27. Isolated B cell populations were either cultured in vitro in the presence of anti-IgM, IL-21 and BAFF on a layer of irradiated CD40L transfected fibroblasts, or left in medium without additional stimulation. Following culture for 6 and/or 13 days, supernatants were assessed for the presence of ACPA-IgG and non-specific total IgG by ELISA.

Results:

Following stimulation, ACPA could be detected in up to 100% of culture wells. Both the average ACPA titer in the wells as well as the percentage of positive wells correlated with measures of disease activity. No reactivity was observed against the arginine containing control antigen. No ACPA production was detectable by B cells isolated from ACPA negative RA patients or healthy controls. Of interest, ACPA were also produced spontaneously ex-vivo without stimulation. Active ACPA production was detectable for extended periods of time (up to 4 weeks). FACS-sorting experiments comparing isolated B cell subsets indicated that spontaneous ACPA production resides, for a large part, in the circulating plasmablast population. Spontaneous ACPA production was still observed after depletion of the CD20 positive B cell population.

Conclusion:

We show that ACPA producing plasmablasts circulate in the peripheral blood of ACPA positive RA patients in a disease activity dependent manner. Ex vivo, these plasmablasts were not short-lived and were not targeted by an anti-CD20 antibody. These observations enhance our understanding of ACPA producing B cells and could be relevant for future targeted therapies.


Disclosure:

P. Kerkman,
None;

E. I. H. van der Voort,
None;

L. A. Trouw,
None;

T. W. J. Huizinga,
None;

R. E. M. Toes,
None;

H. U. Scherer,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/circulating-plasmablasts-as-a-source-of-anti-citrullinated-protein-antibodies-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology